» Articles » PMID: 38642238

Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD FMRI Trial

Overview
Journal Infect Dis Ther
Date 2024 Apr 20
PMID 38642238
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: It is unclear whether neurotoxicity due to the antiretroviral drug efavirenz (EFV) results in neurocognitive impairment in people living with HIV (PLWH). Previously, we found that discontinuing EFV was associated with improved processing speed and attention on neuropsychological assessment. In this imaging study, we investigate potential neural mechanisms underlying this cognitive improvement using a BOLD fMRI task assessing cortical and subcortical functioning.

Methods: Asymptomatic adult PLWH stable on emtricitabine/tenofovirdisoproxil/efavirenz were randomly (1:2) assigned to continue their regimen (n = 12) or to switch to emtricitabine/tenofovirdisoproxil/rilpivirine (n = 28). At baseline and after 12 weeks, both groups performed the Stop-Signal Anticipation Task, which tests reactive and proactive inhibition (indicative of subcortical and cortical functioning, respectively), involving executive functioning, working memory, and attention. Behavior and BOLD fMRI activation levels related to processing speed and attention Z-scores were assessed in 17 pre-defined brain regions.

Results: Both groups had comparable patient and clinical characteristics. Reactive inhibition behavioral responses improved for both groups on week 12, with other responses unchanged. Between-group activation did not differ significantly. For reactive inhibition, positive Pearson coefficients were observed for the change in BOLD fMRI activation levels and change in processing speed and attention Z-scores in all 17 regions in participants switched to emtricitabine/tenofovir disoproxil/rilpivirine, whereas in the control group, negative correlation coefficients were observed in 10/17 and 13/17 regions, respectively. No differential pattern was observed for proactive inhibition.

Conclusion: Potential neural mechanisms underlying cognitive improvement after discontinuing EFV in PLWH were found in subcortical functioning, with our findings suggesting that EFV's effect on attention and processing speed is, at least partially, mediated by reactive inhibition.

Trial Registration: Clinicaltrials.gov identifier [NCT02308332].

Citing Articles

Application status and prospects of multimodal EEG-fMRI in HIV-associated neurocognitive disorders.

Chen J, Luo H, Liu J, Wang W, Ma J, Hou C Front Neurol. 2024; 15:1479197.

PMID: 39703361 PMC: 11655344. DOI: 10.3389/fneur.2024.1479197.


Mechanisms and treatments of methamphetamine and HIV-1 co-induced neurotoxicity: a systematic review.

Miao L, Wang H, Li Y, Huang J, Wang C, Teng H Front Immunol. 2024; 15:1423263.

PMID: 39224601 PMC: 11366655. DOI: 10.3389/fimmu.2024.1423263.

References
1.
Pourcher V, Gourmelen J, Bureau I, Bouee S . Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France. PLoS One. 2020; 15(12):e0243529. PMC: 7746269. DOI: 10.1371/journal.pone.0243529. View

2.
Heaton R, Franklin D, Ellis R, McCutchan J, Letendre S, LeBlanc S . HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2010; 17(1):3-16. PMC: 3032197. DOI: 10.1007/s13365-010-0006-1. View

3.
Ernst T, Chang L, Jovicich J, Ames N, Arnold S . Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology. 2002; 59(9):1343-9. DOI: 10.1212/01.wnl.0000031811.45569.b0. View

4.
Ciavatta V, Bichler E, Speigel I, Elder C, Teng S, Tyor W . In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals. Neurochem Res. 2017; 42(11):3220-3232. DOI: 10.1007/s11064-017-2358-x. View

5.
Baldewicz T, Leserman J, Silva S, Petitto J, Golden R, Perkins D . Changes in neuropsychological functioning with progression of HIV-1 infection: results of an 8-year longitudinal investigation. AIDS Behav. 2004; 8(3):345-55. DOI: 10.1023/B:AIBE.0000044081.42034.54. View